Ipsen: receives positive opinion from CHMP

(CercleFinance.com) - Today Ipsen announced that the CHMP (Committee for Medicinal Products for Human Use), the Scientific Committee of the European Medicines Agency (EMA), has approved Cabometyx (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma (aRCC).


The CHMP's approval will now be subject to a review by the European Commission (EC), which is authorised to approve the drug in the European Union (EU).

The positive CHMP opinion follows EMA approval in 2016 for the treatment of aRCC after prior VEGF-targeted therapy.



Copyright (c) 2018 CercleFinance.com. All rights reserved.